Brainstorm Cell Therapeutics (NASDAQ:BCLI) Posts Earnings Results, Beats Estimates By $0.12 EPS

Brainstorm Cell Therapeutics (NASDAQ:BCLI) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.12, MarketWatch Earnings reports.

Shares of NASDAQ:BCLI opened at $13.86 on Friday. The firm has a fifty day moving average of $14.66 and a two-hundred day moving average of $10.71. The firm has a market capitalization of $437.53 million, a P/E ratio of -11.95 and a beta of 0.83. Brainstorm Cell Therapeutics has a 12-month low of $3.58 and a 12-month high of $17.95.

A number of research analysts recently commented on the stock. Maxim Group raised their price objective on shares of Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. BidaskClub lowered shares of Brainstorm Cell Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Further Reading: What is the Coverage Ratio?

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with's FREE daily email newsletter.